OBJECTIVE: To investigate the impact of depressive symptoms on health-related quality of life (HR-QOL) in a group of patients with early Parkinson's disease (PD). METHODS:A 20-item scale, the Center for Epidemiologic Studies Depression Scale (CESD) and a 36-item questionnaire, the medical outcomes study short form (SF-36) were administered as part of baseline assessment of a clinical trial in PD, enrolling 391 early-stage, L-dopa exposed PD patients in China. We used multiple regression models to examine the relationship of depressive symptoms, measured by the CESD with HR-QOL, as measured by the SF-36. The SF-36 score of the depressed patients was compared with those non-depressed, as well. RESULTS:A total of 146 (37.3%) patients screened positive for depression. Compared with those non-depressed, depressed patients had lower scores in all dimensions of SF-36 profile (p<0.001). Multiple regression analysis revealed that depressive symptoms, measured by CESD, increased our ability to explain the variance of SF-36 total score by 34.5%. Additionally, depressive symptom is the only variable which has the predictive value not only for total SF-36 total score, but also for each subdimension score of SF-36 profile. CONCLUSION:Depressive symptoms are common early in the disease, having a substantial impact on patients' HR-QOL, affecting many areas other than the obvious mental health dimension of the HR-QOL profile. Our results highlight the broad importance of treating depression in this population.
RCT Entities:
OBJECTIVE: To investigate the impact of depressive symptoms on health-related quality of life (HR-QOL) in a group of patients with early Parkinson's disease (PD). METHODS: A 20-item scale, the Center for Epidemiologic Studies Depression Scale (CESD) and a 36-item questionnaire, the medical outcomes study short form (SF-36) were administered as part of baseline assessment of a clinical trial in PD, enrolling 391 early-stage, L-dopa exposed PDpatients in China. We used multiple regression models to examine the relationship of depressive symptoms, measured by the CESD with HR-QOL, as measured by the SF-36. The SF-36 score of the depressedpatients was compared with those non-depressed, as well. RESULTS: A total of 146 (37.3%) patients screened positive for depression. Compared with those non-depressed, depressedpatients had lower scores in all dimensions of SF-36 profile (p<0.001). Multiple regression analysis revealed that depressive symptoms, measured by CESD, increased our ability to explain the variance of SF-36 total score by 34.5%. Additionally, depressive symptom is the only variable which has the predictive value not only for total SF-36 total score, but also for each subdimension score of SF-36 profile. CONCLUSION:Depressive symptoms are common early in the disease, having a substantial impact on patients' HR-QOL, affecting many areas other than the obvious mental health dimension of the HR-QOL profile. Our results highlight the broad importance of treating depression in this population.
Authors: Allison W Willis; Mario Schootman; Rebecca Tran; Nathan Kung; Bradley A Evanoff; Joel S Perlmutter; Brad A Racette Journal: Neurology Date: 2012-10-10 Impact factor: 9.910
Authors: Sze-Ee Soh; Jennifer L McGinley; Jennifer J Watts; Robert Iansek; Anna T Murphy; Hylton B Menz; Frances Huxham; Meg E Morris Journal: Qual Life Res Date: 2012-10-16 Impact factor: 4.147